News
Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...
5d
GlobalData on MSNNovo Nordisk defeated in Wegovy patent dispute by ViatrisThe Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...
Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...
Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...
A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...
6d
Barchart on MSNWhat to Expect From Viatris' Next Quarterly Earnings ReportViatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.
Indiana Attorney General Todd Rokita has secured $720 million in settlements with eight drug makers that manufacture opioid ...
StockStory.org on MSN13h
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals StocksAs the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Healthcare company Viatris has been certified as a Great Place to Work® in both Australia and New Zealand, marking the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results